RebrAIn Company Research Report

Company Overview

• Name: RebrAIn

• Mission: RebrAIn aims to enhance patient outcomes in Parkinson’s Disease and Essential Tremor treatments by combining best-in-class supervised AI with clinically successful results, providing precise brain targeting for Deep Brain Stimulation (DBS) neurosurgery.

• Founding: RebrAIn is a spin-off of the University Hospital of Bordeaux and Inria. It was created after 10 years of academic research and 2 theses.

• Founders: Professor Emmanuel Cuny, Neurosurgeon, and Professor Nejib Zemzemi, a researcher at Inria in Applied Mathematics.

• Key People:

• Emmanuel Cuny (Co-founder, CMO & Board President)

• Nejib Zemzemi (Co-founder, CSO & CTO)

• David Caumartin (CEO)

• Headquarters:

• France: Plateforme Technologique d’Innovation Biomédicale (PTIB), Hôpital Xavier Arnozan, avenue du Haut Lévêque, 33600 Pessac Cedex.

• USA: 2915 Ogletown Road, Newark, Delaware 19713.

• Number of Employees: 10 employees

• Revenue: No information is available

• Known For: RebrAIn is known for revolutionizing precise targeting in neurosurgery through AI-driven solutions for DBS, enhancing patient outcomes, and simplifying surgical procedures.

Products

RebrAIn Services

• Description: A millimetric MRI-guided targeting service that helps plan neurosurgical procedures and enhances patient outcomes in Parkinson's Disease and Essential Tremor treatments.

• Key Features:

• Uses supervised AI algorithms.

• Health data exchange platform.

• CE Marked and FDA 510(k) cleared Software as a Medical Device (SaMD), including OptimMRI and OptimDBS.

• Simplifies and standardizes neurosurgical procedures.

Recent Developments

• Regulatory Approvals:

• The company has obtained CE marking and FDA 510(k) clearance for its software solutions.

• New Products/Features:

• No specific new products or features were listed.

• Partnerships:

• Collaborations with various esteemed medical professionals and institutions for advisory and clinical purposes, including Brigham & Women's Hospital and Mount Sinai New-York.

• Clinical Trials:

• Enrollment completed ahead of schedule for the PARKEO2 clinical trial.

• Clinical trials in Phase 3 for Parkinson's Disease DBS and radiosurgery.

• Publications:

• Publishing results and advancements in precision targeting solutions for medical professionals.

• Presentations:

• Co-founders presented innovative VIM targeting techniques at WSSFN Biennial Meeting.

General Information

RebrAIn focuses on integrating AI-driven platforms with neurosurgical workflows to improve patient care and operational efficiency in hospitals. The company is actively involved in clinical studies to advance DBS targeting, leveraging its technology in over 500 targeting operations across 55 centers worldwide.